

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Alkaline Phosphatase (U/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	67.99	70.94	72.01	70.33
	SD	17.081	19.206	19.065	18.476
	Median	67.00	68.00	71.00	68.00
	Min	42.00	29.00	37.00	29.00
	Max	119.00	125.00	124.00	125.00
Day4	n	69	71	70	210
	Mean	-2.86	-3.92	-3.40	-3.40
	SD	5.608	6.403	6.389	6.134
	Median	-3.00	-4.00	-3.50	-3.00
	Min	-19.00	-25.00	-19.00	-25.00
	Max	11.00	7.00	11.00	11.00
Day8	n	69	71	70	210
	Mean	-1.91	-3.42	-2.43	-2.60
	SD	6.444	7.301	6.296	6.697
	Median	-1.00	-2.00	-2.00	-2.00
	Min	-20.00	-24.00	-18.00	-24.00
	Max	18.00	10.00	9.00	18.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Alkaline Phosphatase (U/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	-1.93	-1.72	-3.17	-2.27
	SD	6.534	7.084	7.993	7.224
	Median	-2.00	-2.00	-3.00	-2.00
	Min	-17.00	-25.00	-30.00	-30.00
	Max	18.00	14.00	15.00	18.00
Day29	n	67	70	70	207
	Mean	-2.37	-2.33	-1.17	-1.95
	SD	7.367	8.316	9.567	8.457
	Median	-3.00	-3.00	-1.00	-2.00
	Min	-16.00	-22.00	-34.00	-34.00
	Max	24.00	26.00	22.00	26.00
Day43	n	67	71	69	207
	Mean	-0.72	-0.10	0.29	-0.17
	SD	6.274	6.955	10.547	8.120
	Median	-2.00	0.00	0.00	0.00
	Min	-13.00	-24.00	-21.00	-24.00
	Max	16.00	14.00	60.00	60.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Alkaline Phosphatase (U/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.06	0.15	-0.14	0.02
	SD	7.991	9.997	10.734	9.607
	Median	-1.00	0.00	-1.00	-0.50
	Min	-21.00	-26.00	-29.00	-29.00
	Max	18.00	42.00	40.00	42.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Protein (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	7.21	7.28	7.19	7.23
	SD	0.395	0.408	0.378	0.394
	Median	7.20	7.20	7.20	7.20
	Min	6.40	6.20	6.40	6.20
	Max	8.20	8.30	8.40	8.40
Day4	n	69	71	70	210
	Mean	-0.16	-0.21	-0.21	-0.19
	SD	0.357	0.347	0.353	0.351
	Median	-0.20	-0.20	-0.20	-0.20
	Min	-1.00	-1.00	-1.00	-1.00
	Max	0.70	0.50	0.70	0.70
Day8	n	69	71	70	210
	Mean	-0.08	-0.15	-0.11	-0.11
	SD	0.334	0.311	0.342	0.329
	Median	-0.10	-0.20	-0.10	-0.10
	Min	-0.90	-0.90	-1.10	-1.10
	Max	0.70	0.50	1.00	1.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Protein (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	-0.06	-0.06	-0.12	-0.08
	SD	0.288	0.339	0.323	0.317
	Median	0.00	-0.10	-0.10	-0.10
	Min	-0.70	-1.20	-1.00	-1.20
	Max	0.60	0.60	0.90	0.90
Day29	n	67	70	70	207
	Mean	-0.00	0.01	0.04	0.02
	SD	0.357	0.323	0.372	0.350
	Median	0.00	0.00	0.00	0.00
	Min	-0.80	-0.70	-1.10	-1.10
	Max	1.40	0.60	1.10	1.40
Day43	n	67	71	69	207
	Mean	0.11	0.05	0.04	0.07
	SD	0.333	0.363	0.326	0.341
	Median	0.10	0.00	0.10	0.10
	Min	-0.70	-1.10	-0.60	-1.10
	Max	0.80	1.10	0.60	1.10

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Protein (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.08	0.03	0.01	0.04
	SD	0.360	0.398	0.365	0.374
	Median	0.00	0.00	0.00	0.00
	Min	-0.80	-0.70	-0.80	-0.80
	Max	1.00	1.00	0.80	1.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Albumin (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	4.57	4.57	4.55	4.56
	SD	0.252	0.239	0.209	0.233
	Median	4.60	4.60	4.60	4.60
	Min	4.00	3.80	4.00	3.80
	Max	5.10	5.30	5.00	5.30
Day4	n	69	71	70	210
	Mean	-0.15	-0.16	-0.16	-0.15
	SD	0.208	0.222	0.210	0.213
	Median	-0.20	-0.20	-0.20	-0.20
	Min	-0.60	-0.80	-0.50	-0.80
	Max	0.40	0.30	0.40	0.40
Day8	n	69	71	70	210
	Mean	-0.08	-0.12	-0.09	-0.10
	SD	0.211	0.176	0.218	0.202
	Median	-0.10	-0.10	-0.10	-0.10
	Min	-0.40	-0.60	-0.50	-0.60
	Max	0.50	0.30	0.60	0.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Albumin (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	-0.06	-0.05	-0.06	-0.06
	SD	0.193	0.192	0.191	0.191
	Median	-0.10	0.00	-0.10	0.00
	Min	-0.50	-0.70	-0.50	-0.70
	Max	0.50	0.50	0.40	0.50
Day29	n	67	70	70	207
	Mean	-0.05	-0.02	0.01	-0.02
	SD	0.229	0.195	0.220	0.215
	Median	-0.10	0.00	0.00	0.00
	Min	-0.50	-0.50	-0.60	-0.60
	Max	0.90	0.40	0.60	0.90
Day43	n	67	71	69	207
	Mean	0.01	-0.02	-0.02	-0.01
	SD	0.222	0.225	0.189	0.212
	Median	0.00	0.00	0.00	0.00
	Min	-0.50	-0.90	-0.40	-0.90
	Max	0.50	0.60	0.40	0.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Albumin (g/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	-0.01	-0.03	-0.05	-0.03
	SD	0.231	0.250	0.231	0.237
	Median	0.00	0.00	-0.10	0.00
	Min	-0.50	-0.60	-0.50	-0.60
	Max	0.50	0.50	0.40	0.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Blood Urea Nitrogen (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	14.86	15.06	15.13	15.01
	SD	4.288	3.320	3.897	3.834
	Median	15.00	15.00	15.00	15.00
	Min	6.00	8.00	4.00	4.00
	Max	24.00	24.00	26.00	26.00
Day4	n	69	71	70	210
	Mean	-0.94	-1.15	-1.23	-1.11
	SD	3.674	2.284	3.070	3.044
	Median	-1.00	-1.00	-1.00	-1.00
	Min	-8.00	-7.00	-9.00	-9.00
	Max	8.00	3.00	5.00	8.00
Day8	n	69	71	70	210
	Mean	-0.67	-0.94	-1.13	-0.91
	SD	3.501	2.720	2.988	3.074
	Median	-1.00	-1.00	-1.00	-1.00
	Min	-7.00	-10.00	-8.00	-10.00
	Max	7.00	5.00	6.00	7.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Blood Urea Nitrogen (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	-0.38	0.34	-0.01	-0.01
	SD	3.214	3.346	3.554	3.371
	Median	0.00	1.00	0.00	0.00
	Min	-8.00	-12.00	-8.00	-12.00
	Max	7.00	8.00	9.00	9.00
Day29	n	67	70	70	207
	Mean	-0.10	0.81	1.16	0.63
	SD	3.215	3.393	4.010	3.583
	Median	0.00	1.00	1.00	1.00
	Min	-7.00	-6.00	-7.00	-7.00
	Max	8.00	10.00	13.00	13.00
Day43	n	67	71	69	207
	Mean	0.12	0.83	0.36	0.44
	SD	3.784	3.282	3.330	3.463
	Median	0.00	0.00	0.00	0.00
	Min	-9.00	-6.00	-8.00	-9.00
	Max	7.00	10.00	6.00	10.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Blood Urea Nitrogen (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.58	-0.13	0.44	0.30
	SD	3.402	3.541	3.403	3.447
	Median	1.00	0.00	0.00	0.00
	Min	-8.00	-10.00	-7.00	-10.00
	Max	8.00	8.00	10.00	10.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Urea (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	41	42	42	125
	Mean	32.51	33.36	35.29	33.73
	SD	9.119	6.945	7.781	8.009
	Median	31.00	33.00	33.50	33.00
	Min	14.00	22.00	23.00	14.00
	Max	52.00	48.00	56.00	56.00
Day4	n	41	42	42	125
	Mean	-0.80	-1.36	-3.17	-1.78
	SD	7.772	4.333	6.910	6.520
	Median	-2.00	-2.00	-4.00	-2.00
	Min	-16.00	-10.00	-19.00	-19.00
	Max	17.00	8.00	11.00	17.00
Day8	n	41	42	42	125
	Mean	-0.61	-1.40	-3.29	-1.78
	SD	7.120	5.964	5.870	6.385
	Median	-1.00	-0.50	-3.00	-2.00
	Min	-14.00	-15.00	-17.00	-17.00
	Max	13.00	11.00	8.00	13.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Urea (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	40	42	42	124
	Mean	-1.23	1.38	-0.93	-0.24
	SD	7.326	8.160	7.507	7.705
	Median	-1.00	4.00	0.50	1.00
	Min	-16.00	-24.00	-17.00	-24.00
	Max	15.00	16.00	14.00	16.00
Day29	n	40	42	42	124
	Mean	0.28	1.64	2.29	1.42
	SD	7.154	6.778	9.382	7.847
	Median	1.00	2.00	1.00	1.50
	Min	-15.00	-10.00	-12.00	-15.00
	Max	11.00	21.00	28.00	28.00
Day43	n	39	42	41	122
	Mean	-0.03	2.67	-0.24	0.83
	SD	8.018	7.274	6.935	7.471
	Median	0.00	2.00	0.00	0.00
	Min	-19.00	-10.00	-15.00	-19.00
	Max	13.00	22.00	12.00	22.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Urea (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	41	42	42	125
	Mean	1.20	-0.24	-0.50	0.14
	SD	7.795	7.258	6.597	7.209
	Median	2.00	0.00	-1.00	0.00
	Min	-16.00	-13.00	-15.00	-16.00
	Max	17.00	16.00	22.00	22.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Creatinine (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	0.97	0.99	0.96	0.97
	SD	0.133	0.163	0.126	0.141
	Median	1.00	1.00	0.90	1.00
	Min	0.70	0.60	0.70	0.60
	Max	1.40	1.40	1.30	1.40
Day4	n	69	71	70	210
	Mean	0.01	-0.00	-0.00	0.00
	SD	0.084	0.082	0.083	0.082
	Median	0.00	0.00	0.00	0.00
	Min	-0.20	-0.20	-0.20	-0.20
	Max	0.20	0.20	0.20	0.20
Day8	n	69	71	70	210
	Mean	-0.00	-0.01	-0.01	-0.00
	SD	0.080	0.092	0.089	0.087
	Median	0.00	0.00	0.00	0.00
	Min	-0.20	-0.30	-0.30	-0.30
	Max	0.20	0.20	0.20	0.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Creatinine (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.03	0.01	0.02	0.02
	SD	0.090	0.103	0.078	0.091
	Median	0.00	0.00	0.00	0.00
	Min	-0.20	-0.30	-0.20	-0.30
	Max	0.20	0.40	0.20	0.40
Day29	n	67	70	70	207
	Mean	0.00	0.00	0.02	0.01
	SD	0.090	0.094	0.089	0.091
	Median	0.00	0.00	0.00	0.00
	Min	-0.20	-0.20	-0.20	-0.20
	Max	0.20	0.20	0.20	0.20
Day43	n	67	71	69	207
	Mean	0.02	0.02	0.00	0.02
	SD	0.095	0.102	0.091	0.096
	Median	0.00	0.00	0.00	0.00
	Min	-0.20	-0.20	-0.30	-0.30
	Max	0.20	0.30	0.20	0.30

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Creatinine (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.02	0.02	0.02	0.02
	SD	0.084	0.094	0.078	0.085
	Median	0.00	0.00	0.00	0.00
	Min	-0.20	-0.20	-0.20	-0.20
	Max	0.20	0.20	0.20	0.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Urate (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	5.81	5.94	5.77	5.84
	SD	0.998	1.045	0.961	1.000
	Median	5.70	6.10	5.70	5.80
	Min	3.80	3.40	3.90	3.40
	Max	8.20	8.70	8.10	8.70
Day4	n	69	71	70	210
	Mean	-0.07	-0.14	-0.10	-0.10
	SD	0.638	0.638	0.659	0.643
	Median	-0.20	-0.10	-0.10	-0.10
	Min	-1.30	-2.40	-2.20	-2.40
	Max	1.40	1.50	1.30	1.50
Day8	n	69	71	70	210
	Mean	-0.17	-0.23	-0.17	-0.19
	SD	0.591	0.627	0.651	0.621
	Median	-0.20	-0.20	-0.10	-0.15
	Min	-1.90	-2.00	-1.70	-2.00
	Max	1.10	1.10	1.60	1.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Urate (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.13	0.20	0.16	0.16
	SD	0.668	0.718	0.713	0.698
	Median	0.10	0.20	0.20	0.20
	Min	-1.40	-1.50	-1.60	-1.60
	Max	1.50	1.80	1.80	1.80
Day29	n	67	70	70	207
	Mean	0.09	0.08	0.14	0.10
	SD	0.573	0.774	0.757	0.706
	Median	0.00	0.10	0.20	0.10
	Min	-1.30	-2.10	-1.70	-2.10
	Max	1.30	2.00	2.00	2.00
Day43	n	67	71	69	207
	Mean	0.14	0.15	0.08	0.12
	SD	0.776	0.709	0.725	0.733
	Median	0.10	0.00	0.20	0.10
	Min	-1.30	-1.40	-2.00	-2.00
	Max	1.90	2.50	1.90	2.50

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Urate (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.09	0.10	0.04	0.08
	SD	0.684	0.705	0.683	0.688
	Median	0.10	0.20	0.20	0.20
	Min	-1.20	-1.80	-1.70	-1.80
	Max	2.20	2.00	1.40	2.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Sodium (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	140.74	140.49	140.74	140.66
	SD	2.153	1.999	1.916	2.018
	Median	141.00	140.00	141.00	141.00
	Min	134.00	136.00	137.00	134.00
	Max	144.00	146.00	146.00	146.00
Day4	n	69	71	70	210
	Mean	0.06	0.23	-0.14	0.05
	SD	1.893	1.709	1.627	1.744
	Median	0.00	0.00	0.00	0.00
	Min	-4.00	-4.00	-4.00	-4.00
	Max	7.00	4.00	3.00	7.00
Day8	n	69	71	70	210
	Mean	0.48	0.69	0.41	0.53
	SD	2.207	2.088	1.869	2.052
	Median	0.00	1.00	0.00	0.00
	Min	-4.00	-4.00	-4.00	-4.00
	Max	9.00	5.00	5.00	9.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Sodium (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.41	-0.04	0.20	0.19
	SD	1.949	2.114	2.227	2.099
	Median	0.50	0.00	0.00	0.00
	Min	-4.00	-5.00	-5.00	-5.00
	Max	7.00	7.00	7.00	7.00
Day29	n	67	70	70	207
	Mean	-0.10	-0.06	0.24	0.03
	SD	1.908	1.918	2.060	1.961
	Median	0.00	0.00	0.00	0.00
	Min	-5.00	-6.00	-4.00	-6.00
	Max	6.00	5.00	5.00	6.00
Day43	n	67	71	69	207
	Mean	-0.27	-0.28	-0.49	-0.35
	SD	1.610	1.868	1.884	1.789
	Median	0.00	0.00	-1.00	0.00
	Min	-4.00	-5.00	-4.00	-5.00
	Max	3.00	5.00	5.00	5.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Sodium (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.06	-0.34	-0.10	-0.13
	SD	1.955	1.594	1.942	1.835
	Median	0.00	0.00	0.00	0.00
	Min	-5.00	-3.00	-5.00	-5.00
	Max	7.00	3.00	4.00	7.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Potassium (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	4.27	4.28	4.29	4.28
	SD	0.295	0.336	0.311	0.313
	Median	4.30	4.20	4.30	4.25
	Min	3.70	3.60	3.70	3.60
	Max	5.00	5.00	5.00	5.00
Day4	n	69	71	70	210
	Mean	0.17	0.15	0.18	0.17
	SD	0.334	0.351	0.383	0.355
	Median	0.20	0.10	0.15	0.10
	Min	-0.50	-0.80	-0.70	-0.80
	Max	1.10	1.10	1.10	1.10
Day8	n	69	71	70	210
	Mean	0.21	0.23	0.23	0.22
	SD	0.343	0.365	0.372	0.359
	Median	0.20	0.30	0.20	0.20
	Min	-0.50	-0.70	-0.90	-0.90
	Max	1.10	1.10	1.20	1.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Potassium (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.05	0.10	0.14	0.10
	SD	0.376	0.403	0.345	0.376
	Median	0.00	0.10	0.10	0.10
	Min	-0.70	-1.20	-0.70	-1.20
	Max	1.00	1.10	1.20	1.20
Day29	n	67	70	70	207
	Mean	-0.01	0.04	-0.01	0.01
	SD	0.349	0.346	0.457	0.386
	Median	0.00	0.05	0.00	0.00
	Min	-0.80	-0.70	-1.40	-1.40
	Max	1.00	0.90	0.90	1.00
Day43	n	67	71	69	207
	Mean	0.11	0.02	0.05	0.06
	SD	0.380	0.380	0.464	0.409
	Median	0.10	0.00	0.10	0.10
	Min	-0.70	-1.30	-1.50	-1.50
	Max	1.60	1.00	1.30	1.60

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Potassium (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.05	-0.01	0.06	0.03
	SD	0.364	0.408	0.375	0.382
	Median	0.00	0.00	0.10	0.00
	Min	-0.70	-1.10	-1.00	-1.10
	Max	1.20	1.10	1.10	1.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Chloride (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	104.13	103.69	103.76	103.86
	SD	2.885	2.556	2.109	2.530
	Median	104.00	104.00	104.00	104.00
	Min	99.00	98.00	99.00	98.00
	Max	111.00	109.00	110.00	111.00
Day4	n	69	71	70	210
	Mean	0.39	0.56	0.80	0.59
	SD	2.613	2.341	2.262	2.403
	Median	0.00	0.00	1.00	0.50
	Min	-6.00	-4.00	-4.00	-6.00
	Max	6.00	6.00	10.00	10.00
Day8	n	69	71	70	210
	Mean	0.06	0.35	0.16	0.19
	SD	2.617	2.547	2.040	2.407
	Median	0.00	0.00	0.00	0.00
	Min	-5.00	-8.00	-4.00	-8.00
	Max	6.00	6.00	5.00	6.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Chloride (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.46	0.54	0.75	0.58
	SD	2.494	1.881	1.951	2.116
	Median	0.00	1.00	1.00	1.00
	Min	-5.00	-4.00	-4.00	-5.00
	Max	6.00	4.00	5.00	6.00
Day29	n	67	70	70	207
	Mean	0.31	0.26	0.66	0.41
	SD	2.530	1.847	2.383	2.264
	Median	1.00	0.00	1.00	1.00
	Min	-6.00	-4.00	-7.00	-7.00
	Max	7.00	4.00	6.00	7.00
Day43	n	67	71	69	207
	Mean	0.39	0.63	0.48	0.50
	SD	2.424	2.934	2.649	2.671
	Median	0.00	1.00	1.00	1.00
	Min	-6.00	-9.00	-6.00	-9.00
	Max	7.00	9.00	8.00	9.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Chloride (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.41	0.10	0.66	0.39
	SD	2.686	2.689	2.277	2.556
	Median	0.00	0.00	1.00	0.00
	Min	-5.00	-7.00	-6.00	-7.00
	Max	8.00	6.00	7.00	8.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Calcium (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	9.66	9.66	9.69	9.67
	SD	0.330	0.339	0.363	0.343
	Median	9.60	9.60	9.70	9.65
	Min	8.80	8.90	8.80	8.80
	Max	10.40	10.70	10.50	10.70
Day4	n	69	71	70	210
	Mean	0.03	-0.03	-0.01	-0.00
	SD	0.309	0.331	0.345	0.328
	Median	0.00	0.00	0.00	0.00
	Min	-0.70	-0.70	-0.90	-0.90
	Max	0.80	0.70	0.80	0.80
Day8	n	69	71	70	210
	Mean	0.10	0.08	0.07	0.08
	SD	0.300	0.272	0.345	0.306
	Median	0.10	0.10	0.10	0.10
	Min	-0.50	-0.40	-1.00	-1.00
	Max	0.70	0.80	0.90	0.90

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Calcium (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	-0.01	0.02	-0.04	-0.01
	SD	0.322	0.396	0.356	0.359
	Median	0.00	0.00	0.00	0.00
	Min	-0.60	-1.20	-1.20	-1.20
	Max	0.90	0.70	0.80	0.90
Day29	n	67	70	70	207
	Mean	-0.04	0.02	-0.02	-0.01
	SD	0.348	0.366	0.376	0.363
	Median	-0.10	0.10	0.00	0.00
	Min	-0.90	-0.90	-1.60	-1.60
	Max	0.70	0.70	0.70	0.70
Day43	n	67	71	69	207
	Mean	0.09	0.02	-0.01	0.03
	SD	0.351	0.358	0.366	0.359
	Median	0.10	0.10	0.00	0.00
	Min	-0.80	-1.00	-0.80	-1.00
	Max	0.70	0.90	0.80	0.90

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Calcium (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.07	0.04	0.03	0.05
	SD	0.388	0.364	0.345	0.365
	Median	0.00	0.10	0.05	0.10
	Min	-0.90	-0.90	-0.70	-0.90
	Max	1.20	0.70	1.00	1.20

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Bicarbonate (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	28.45	28.48	28.40	28.44
	SD	2.323	2.229	2.183	2.235
	Median	28.00	28.00	29.00	28.50
	Min	23.00	24.00	24.00	23.00
	Max	34.00	33.00	33.00	34.00
Day4	n	69	71	70	210
	Mean	0.48	-0.04	0.50	0.31
	SD	2.483	2.283	1.962	2.255
	Median	0.00	0.00	1.00	0.00
	Min	-6.00	-5.00	-5.00	-6.00
	Max	6.00	7.00	4.00	7.00
Day8	n	69	71	70	210
	Mean	1.15	1.33	1.27	1.25
	SD	2.616	2.406	2.060	2.360
	Median	1.00	2.00	1.00	1.00
	Min	-5.00	-5.00	-4.00	-5.00
	Max	8.00	6.00	6.00	8.00

Baseline is defined as the most recent measurement prior to dosing.
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
 If two tests have equal distance to the target day, then the later one will be used.
 Study Day is based on time windows.
 Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Bicarbonate (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	0.74	0.06	0.29	0.36
	SD	2.566	2.335	2.371	2.429
	Median	1.00	0.00	0.00	0.00
	Min	-8.00	-6.00	-9.00	-9.00
	Max	6.00	6.00	5.00	6.00
Day29	n	67	70	70	207
	Mean	0.10	-0.09	-0.04	-0.01
	SD	2.934	2.055	2.398	2.471
	Median	0.00	0.00	0.00	0.00
	Min	-8.00	-5.00	-6.00	-8.00
	Max	6.00	6.00	4.00	6.00
Day43	n	67	71	69	207
	Mean	0.45	0.00	0.09	0.17
	SD	2.464	2.070	2.466	2.334
	Median	0.00	0.00	0.00	0.00
	Min	-5.00	-5.00	-5.00	-5.00
	Max	7.00	5.00	8.00	8.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Bicarbonate (Meq/L)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	0.19	0.14	0.04	0.12
	SD	2.322	2.072	2.010	2.128
	Median	0.00	0.00	0.00	0.00
	Min	-6.00	-4.00	-6.00	-6.00
	Max	6.00	4.00	4.00	6.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: pH

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	6.14	5.93	5.91	5.99
	SD	0.907	0.762	0.812	0.831
	Median	6.00	6.00	6.00	6.00
	Min	5.00	5.00	5.00	5.00
	Max	8.00	8.00	8.00	8.00
Day4	n	0	1	1	2
	Mean	-	0.00	-0.50	-0.25
	SD	-	-	-	0.354
	Median	-	0.00	-0.50	-0.25
	Min	-	0.00	-0.50	-0.50
	Max	-	0.00	-0.50	0.00
Day8	n	69	71	70	210
	Mean	-0.59	-0.37	-0.36	-0.44
	SD	0.966	0.922	0.913	0.935
	Median	-0.50	0.00	0.00	0.00
	Min	-3.00	-2.50	-3.00	-3.00
	Max	2.00	2.00	1.00	2.00

Baseline is defined as the most recent measurement prior to dosing.
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
 If two tests have equal distance to the target day, then the later one will be used.
 Study Day is based on time windows.
 Lab results in standard units have been used in the presentation.

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: pH

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	1	1	0	2
	Mean	-1.50	2.00	-	0.25
	SD	-	-	-	2.475
	Median	-1.50	2.00	-	0.25
	Min	-1.50	2.00	-	-1.50
	Max	-1.50	2.00	-	2.00
Day29	n	67	70	69	206
	Mean	-0.37	-0.11	-0.15	-0.21
	SD	0.967	0.932	0.937	0.947
	Median	0.00	0.00	0.00	0.00
	Min	-3.00	-2.00	-3.00	-3.00
	Max	2.00	2.00	2.00	2.00
Day43	n	67	71	69	207
	Mean	-0.42	-0.19	-0.04	-0.21
	SD	1.039	0.994	1.055	1.036
	Median	0.00	0.00	0.00	0.00
	Min	-3.00	-3.00	-3.00	-3.00
	Max	2.00	2.00	3.00	3.00

Baseline is defined as the most recent measurement prior to dosing.
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
 If two tests have equal distance to the target day, then the later one will be used.
 Study Day is based on time windows.
 Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: pH

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	-0.25	-0.12	-0.10	-0.16
	SD	1.140	0.888	0.854	0.965
	Median	0.00	0.00	0.00	0.00
	Min	-3.00	-3.00	-2.00	-3.00
	Max	3.00	2.00	3.00	3.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Glucose (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Baseline	n	69	71	70	210
	Mean	88.58	88.28	87.50	88.12
	SD	7.521	8.283	6.292	7.393
	Median	88.00	87.00	88.00	87.00
	Min	72.00	71.00	75.00	71.00
	Max	111.00	117.00	104.00	117.00
Day4	n	69	71	70	210
	Mean	-1.65	-0.61	-0.23	-0.82
	SD	6.382	7.054	6.483	6.645
	Median	-1.00	-1.00	0.00	-1.00
	Min	-17.00	-27.00	-22.00	-27.00
	Max	19.00	14.00	14.00	19.00
Day8	n	69	71	70	210
	Mean	-2.90	-2.82	-1.21	-2.31
	SD	6.526	6.931	6.138	6.557
	Median	-3.00	-3.00	-1.00	-2.00
	Min	-19.00	-24.00	-25.00	-25.00
	Max	12.00	14.00	14.00	14.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Glucose (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day15	n	68	71	69	208
	Mean	3.32	2.75	2.86	2.97
	SD	8.631	7.559	7.429	7.850
	Median	2.50	3.00	4.00	3.00
	Min	-22.00	-25.00	-17.00	-25.00
	Max	37.00	20.00	18.00	37.00
Day29	n	67	70	70	207
	Mean	3.16	2.69	3.94	3.27
	SD	8.508	7.906	7.638	7.996
	Median	3.00	3.00	3.00	3.00
	Min	-19.00	-19.00	-16.00	-19.00
	Max	23.00	21.00	23.00	23.00
Day43	n	67	71	69	207
	Mean	3.45	4.08	2.93	3.49
	SD	8.892	15.691	7.277	11.256
	Median	2.00	2.00	3.00	3.00
	Min	-12.00	-17.00	-20.00	-20.00
	Max	27.00	115.00	22.00	115.00

Baseline is defined as the most recent measurement prior to dosing.

If more than one test fall into the same window, then the one closer to the target day will be selected for the window.

If two tests have equal distance to the target day, then the later one will be used.

Study Day is based on time windows.

Lab results in standard units have been used in the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.1 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:17)

Table 14.3.4.1.2.2
PF-06410293 Protocol B5381001
Mean Baseline and Change from Baseline for Laboratory Data - Safety Analysis Set
Parameter: Glucose (mg/dL)

		Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Study Day					
Day71	n	69	71	70	210
	Mean	1.01	2.80	2.69	2.18
	SD	8.586	8.607	8.861	8.682
	Median	1.00	3.00	3.00	2.00
	Min	-24.00	-18.00	-24.00	-24.00
	Max	25.00	30.00	23.00	30.00

090177e18e74aa75\Final\Final On: 30-May-2018 05:31 (GMT)

Baseline is defined as the most recent measurement prior to dosing.
 If more than one test fall into the same window, then the one closer to the target day will be selected for the window.
 If two tests have equal distance to the target day, then the later one will be used.
 Study Day is based on time windows.
 Lab results in standard units have been used in the presentation.

Table 14.3.4.1.3
PF-06410293 Protocol B5381001
Summary of Laboratory Results - eDISH Analysis - Safety Analysis Set
ALT or AST or total Bilirubin baseline is high

Treatment	N	Normal Bilirubin and AST ALT n (%)	Temple's Corollary (AST ALT>=3*ULN and Normal Bilirubin) n (%)	Gilbert's Syndrome or Cholestasis (Normal AST ALT and Bilirubin>=2*ULN) n (%)	AST ALT>=3*ULN and Bilirubin>=2*ULN n (%)
Adalimumab-Pfizer	6	6 (100.0)	0	0	0
Adalimumab-US	6	6 (100.0)	0	0	0
Adalimumab-EU	6	5 (83.3)	1 (16.7)	0	0
Total	18	17 (94.4)	1 (5.6)	0	0

090177e18e74aa76\Final\Final On: 30-May-2018 05:32 (GMT)

ULN - Upper Limit of Normal

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.4

Date of SDTM Dataset Creation: 11MAY2018

Date of Table Generation: 15MAY2018 (21:11)

Table 14.3.4.1.3
PF-06410293 Protocol B5381001
Summary of Laboratory Results - eDISH Analysis - Safety Analysis Set
AST and ALT and total Bilirubin baseline is missing, low or normal

Treatment	N	Normal Bilirubin and AST ALT n (%)	Temple's Corollary (AST ALT>=3*ULN and Normal Bilirubin) n (%)	Gilbert's Syndrome or Cholestasis (Normal AST ALT and Bilirubin>=2*ULN) n (%)	AST ALT>=3*ULN and Bilirubin>=2*ULN n (%)
Adalimumab-Pfizer	63	62 (98.4)	0	1 (1.6)	0
Adalimumab-US	65	63 (96.9)	1 (1.5)	1 (1.5)	0
Adalimumab-EU	64	62 (96.9)	2 (3.1)	0	0
Total	192	187 (97.4)	3 (1.6)	2 (1.0)	0

090177e18e74aa76\Final\Final On: 30-May-2018 05:32 (GMT)

ULN - Upper Limit of Normal

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.4

Date of SDTM Dataset Creation: 11MAY2018

Date of Table Generation: 15MAY2018 (21:11)

Table 14.3.4.1.5.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Adalimumab-Pfizer					
	N	Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ANEMIA	69	68 (98.6)	1 (1.4)	0	0	0
HEMOGLOBIN INCREASED	69	67 (97.1)	2 (2.9)	0	0	0
LYMPHOCYTE COUNT DECREASED	69	68 (98.6)	1 (1.4)	0	0	0
LYMPHOCYTE COUNT INCREASED	69	68 (98.6)	0	1 (1.4)	0	0
NEUTROPHIL COUNT DECREASED	69	65 (94.2)	0	4 (5.8)	0	0
PLATELET COUNT DECREASED	69	64 (92.8)	5 (7.2)	0	0	0
WHITE BLOOD CELL DECREASED	69	62 (89.9)	7 (10.1)	0	0	0

090177e18e74aa77\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.5.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Adalimumab-US					
	N	Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ANEMIA	71	70 (98.6)	1 (1.4)	0	0	0
HEMOGLOBIN INCREASED	71	67 (94.4)	4 (5.6)	0	0	0
LYMPHOCYTE COUNT DECREASED	71	71 (100.0)	0	0	0	0
LYMPHOCYTE COUNT INCREASED	71	70 (98.6)	0	1 (1.4)	0	0
NEUTROPHIL COUNT DECREASED	71	65 (91.5)	0	5 (7.0)	1 (1.4)	0
PLATELET COUNT DECREASED	71	67 (94.4)	4 (5.6)	0	0	0
WHITE BLOOD CELL DECREASED	71	63 (88.7)	7 (9.9)	1 (1.4)	0	0

090177e18e74aa77\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.5.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Adalimumab-EU					
	N	Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ANEMIA	70	68 (97.1)	2 (2.9)	0	0	0
HEMOGLOBIN INCREASED	70	66 (94.3)	4 (5.7)	0	0	0
LYMPHOCYTE COUNT DECREASED	70	70 (100.0)	0	0	0	0
LYMPHOCYTE COUNT INCREASED	70	68 (97.1)	0	2 (2.9)	0	0
NEUTROPHIL COUNT DECREASED	70	64 (91.4)	1 (1.4)	5 (7.1)	0	0
PLATELET COUNT DECREASED	70	65 (92.9)	5 (7.1)	0	0	0
WHITE BLOOD CELL DECREASED	70	60 (85.7)	9 (12.9)	1 (1.4)	0	0

090177e18e74aa77\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.5.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	N	Total				
		Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ANEMIA	210	206 (98.1)	4 (1.9)	0	0	0
HEMOGLOBIN INCREASED	210	200 (95.2)	10 (4.8)	0	0	0
LYMPHOCYTE COUNT DECREASED	210	209 (99.5)	1 (0.5)	0	0	0
LYMPHOCYTE COUNT INCREASED	210	206 (98.1)	0	4 (1.9)	0	0
NEUTROPHIL COUNT DECREASED	210	194 (92.4)	1 (0.5)	14 (6.7)	1 (0.5)	0
PLATELET COUNT DECREASED	210	196 (93.3)	14 (6.7)	0	0	0
WHITE BLOOD CELL DECREASED	210	185 (88.1)	23 (11.0)	2 (1.0)	0	0

090177e18e74aa77\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
ANEMIA	Adalimumab-Pfizer	69	OTR*	67	(97.1)	1	(1.4)	0		0		0		68	(98.6)
			Grade 1	1	(1.4)	0		0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(98.6)	1	(1.4)	0		0		0		69	(100.0)
	Adalimumab-US	71	OTR*	70	(98.6)	1	(1.4)	0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	70	(98.6)	1	(1.4)	0		0		0		71	(100.0)
	Adalimumab-EU	70	OTR*	68	(97.1)	2	(2.9)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(97.1)	2	(2.9)	0		0		0		70	(100.0)
	Total	210	OTR*	205	(97.6)	4	(1.9)	0		0		0		209	(99.5)
			Grade 1	1	(0.5)	0		0		0		0		1	(0.5)
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			206	(98.1)	4	(1.9)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:11)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HEMOGLOBIN INCREASED	Adalimumab-Pfizer	69	OTR*	67	(97.1)	2	(2.9)	0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(97.1)	2	(2.9)	0		0		0		69	(100.0)
	Adalimumab-US	71	OTR*	67	(94.4)	2	(2.8)	0		0		0		69	(97.2)
			Grade 1	0		2	(2.8)	0		0		0		2	(2.8)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(94.4)	4	(5.6)	0		0		0		71	(100.0)
	Adalimumab-EU	70	OTR*	66	(94.3)	4	(5.7)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	66	(94.3)	4	(5.7)	0		0		0		70	(100.0)
	Total	210	OTR*	200	(95.2)	8	(3.8)	0		0		0		208	(99.0)
			Grade 1	0		2	(1.0)	0		0		0		2	(1.0)
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			200	(95.2)	10	(4.8)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:11)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
LYMPHOCYTE COUNT DECREASED	Adalimumab-Pfizer	69	OTR*	68	(98.6)	0		0		0		0		68	(98.6)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(98.6)	1	(1.4)	0		0		0		69	(100.0)
	Adalimumab-US	71	OTR*	71	(100.0)	0		0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	71	(100.0)	0		0		0		0		71	(100.0)
	Adalimumab-EU	70	OTR*	70	(100.0)	0		0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	70	(100.0)	0		0		0		0		70	(100.0)
	Total	210	OTR*	209	(99.5)	0		0		0		0		209	(99.5)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		1	(0.5)	0		0		0		1	(0.5)
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			209	(99.5)	1	(0.5)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

090177e18e74aa78\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
LYMPHOCYTE COUNT INCREASED	Adalimumab-Pfizer	69	OTR*	68	(98.6)	0		1	(1.4)	0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(98.6)	0		1	(1.4)	0		0		69	(100.0)
	Adalimumab-US	71	OTR*	70	(98.6)	0		1	(1.4)	0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	70	(98.6)	0		1	(1.4)	0		0		71	(100.0)
	Adalimumab-EU	70	OTR*	68	(97.1)	0		2	(2.9)	0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(97.1)	0		2	(2.9)	0		0		70	(100.0)
	Total	210	OTR*	206	(98.1)	0		4	(1.9)	0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			206	(98.1)	0		4	(1.9)	0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:11)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
NEUTROPHIL COUNT DECREASED	Adalimumab-Pfizer	69	OTR*	65	(94.2)	0		4	(5.8)	0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	65	(94.2)	0		4	(5.8)	0		0		69	(100.0)
	Adalimumab-US	71	OTR*	65	(91.5)	0		5	(7.0)	1	(1.4)	0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	65	(91.5)	0		5	(7.0)	1	(1.4)	0		71	(100.0)
	Adalimumab-EU	70	OTR*	64	(91.4)	1	(1.4)	5	(7.1)	0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	64	(91.4)	1	(1.4)	5	(7.1)	0		0		70	(100.0)
	Total	210	OTR*	194	(92.4)	1	(0.5)	14	(6.7)	1	(0.5)	0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			194	(92.4)	1	(0.5)	14	(6.7)	1	(0.5)	0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

090177e18e74aa78\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
PLATELET COUNT DECREASED	Adalimumab-Pfizer	69	OTR*	64	(92.8)	4	(5.8)	0		0		0		68	(98.6)
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	64	(92.8)	5	(7.2)	0		0		0		69	(100.0)
	Adalimumab-US	71	OTR*	67	(94.4)	3	(4.2)	0		0		0		70	(98.6)
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(94.4)	4	(5.6)	0		0		0		71	(100.0)
	Adalimumab-EU	70	OTR*	65	(92.9)	5	(7.1)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	65	(92.9)	5	(7.1)	0		0		0		70	(100.0)
	Total	210	OTR*	196	(93.3)	12	(5.7)	0		0		0		208	(99.0)
			Grade 1	0		2	(1.0)	0		0		0		2	(1.0)
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			196	(93.3)	14	(6.7)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:11)

Table 14.3.4.1.5.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Hematology) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				OTR*		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
WHITE BLOOD CELL DECREASED	Adalimumab-Pfizer	69	OTR*	62	(89.9)	7	(10.1)	0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	62	(89.9)	7	(10.1)	0		0		0		69	(100.0)
	Adalimumab-US	71	OTR*	63	(88.7)	7	(9.9)	0		0		0		70	(98.6)
			Grade 1	0		0		1	(1.4)	0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	63	(88.7)	7	(9.9)	1	(1.4)	0		0		71	(100.0)
	Adalimumab-EU	70	OTR*	60	(85.7)	9	(12.9)	1	(1.4)	0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	60	(85.7)	9	(12.9)	1	(1.4)	0		0		70	(100.0)
	Total	210	OTR*	185	(88.1)	23	(11.0)	1	(0.5)	0		0		209	(99.5)
			Grade 1	0		0		1	(0.5)	0		0		1	(0.5)
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			185	(88.1)	23	(11.0)	2	(1.0)	0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

090177e18e74aa78\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	N	Adalimumab-Pfizer				
		Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ALANINE AMINOTRANSFERASE INCREASED	69	63 (91.3)	6 (8.7)	0	0	0
ALKALINE PHOSPHATASE INCREASED	69	69 (100.0)	0	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED	69	65 (94.2)	4 (5.8)	0	0	0
BLOOD BILIRUBIN INCREASED	69	59 (85.5)	7 (10.1)	3 (4.3)	0	0
CREATININE INCREASED	69	25 (36.2)	44 (63.8)	0	0	0
HYPERCALCEMIA	69	62 (89.9)	7 (10.1)	0	0	0
HYPERGLYCEMIA	69	63 (91.3)	6 (8.7)	0	0	0
HYPERKALEMIA	69	67 (97.1)	1 (1.4)	1 (1.4)	0	0
HYPERNATREMIA	69	67 (97.1)	2 (2.9)	0	0	0
HYPOALBUMINEMIA	69	69 (100.0)	0	0	0	0
HYPOCALCEMIA	69	69 (100.0)	0	0	0	0
HYPOGLYCEMIA	69	69 (100.0)	0	0	0	0
HYPOKALEMIA	69	69 (100.0)	0	0	0	0
HYPONATREMIA	69	68 (98.6)	1 (1.4)	0	0	0

090177e18e74aa79\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Adalimumab-US					
	N	Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ALANINE AMINOTRANSFERASE INCREASED	71	51 (71.8)	19 (26.8)	0	1 (1.4)	0
ALKALINE PHOSPHATASE INCREASED	71	69 (97.2)	2 (2.8)	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED	71	58 (81.7)	12 (16.9)	0	1 (1.4)	0
BLOOD BILIRUBIN INCREASED	71	59 (83.1)	11 (15.5)	1 (1.4)	0	0
CREATININE INCREASED	71	27 (38.0)	44 (62.0)	0	0	0
HYPERCALCEMIA	71	63 (88.7)	8 (11.3)	0	0	0
HYPERGLYCEMIA	71	61 (85.9)	9 (12.7)	1 (1.4)	0	0
HYPERKALEMIA	71	65 (91.5)	4 (5.6)	2 (2.8)	0	0
HYPERNATREMIA	71	68 (95.8)	3 (4.2)	0	0	0
HYPOALBUMINEMIA	71	71 (100.0)	0	0	0	0
HYPOCALCEMIA	71	71 (100.0)	0	0	0	0
HYPOGLYCEMIA	71	71 (100.0)	0	0	0	0
HYPOKALEMIA	71	70 (98.6)	0	1 (1.4)	0	0
HYPONATREMIA	71	65 (91.5)	6 (8.5)	0	0	0

090177e18e74aa79\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Adalimumab-EU					
	N	Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ALANINE AMINOTRANSFERASE INCREASED	70	61 (87.1)	7 (10.0)	1 (1.4)	1 (1.4)	0
ALKALINE PHOSPHATASE INCREASED	70	69 (98.6)	1 (1.4)	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED	70	58 (82.9)	10 (14.3)	1 (1.4)	1 (1.4)	0
BLOOD BILIRUBIN INCREASED	70	64 (91.4)	5 (7.1)	1 (1.4)	0	0
CREATININE INCREASED	70	23 (32.9)	47 (67.1)	0	0	0
HYPERCALCEMIA	70	61 (87.1)	9 (12.9)	0	0	0
HYPERGLYCEMIA	70	65 (92.9)	5 (7.1)	0	0	0
HYPERKALEMIA	70	63 (90.0)	6 (8.6)	1 (1.4)	0	0
HYPERNATREMIA	70	67 (95.7)	3 (4.3)	0	0	0
HYPOALBUMINEMIA	70	70 (100.0)	0	0	0	0
HYPOCALCEMIA	70	70 (100.0)	0	0	0	0
HYPOGLYCEMIA	70	69 (98.6)	1 (1.4)	0	0	0
HYPOKALEMIA	70	68 (97.1)	0	2 (2.9)	0	0
HYPONATREMIA	70	67 (95.7)	3 (4.3)	0	0	0

090177e18e74aa79\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.1
PF-06410293 Protocol B5381001
Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	N	Total				
		Grade 0 n (%)	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
ALANINE AMINOTRANSFERASE INCREASED	210	175 (83.3)	32 (15.2)	1 (0.5)	2 (1.0)	0
ALKALINE PHOSPHATASE INCREASED	210	207 (98.6)	3 (1.4)	0	0	0
ASPARTATE AMINOTRANSFERASE INCREASED	210	181 (86.2)	26 (12.4)	1 (0.5)	2 (1.0)	0
BLOOD BILIRUBIN INCREASED	210	182 (86.7)	23 (11.0)	5 (2.4)	0	0
CREATININE INCREASED	210	75 (35.7)	135 (64.3)	0	0	0
HYPERCALCEMIA	210	186 (88.6)	24 (11.4)	0	0	0
HYPERGLYCEMIA	210	189 (90.0)	20 (9.5)	1 (0.5)	0	0
HYPERKALEMIA	210	195 (92.9)	11 (5.2)	4 (1.9)	0	0
HYPERNATREMIA	210	202 (96.2)	8 (3.8)	0	0	0
HYPOALBUMINEMIA	210	210 (100.0)	0	0	0	0
HYPOCALCEMIA	210	210 (100.0)	0	0	0	0
HYPOGLYCEMIA	210	209 (99.5)	1 (0.5)	0	0	0
HYPOKALEMIA	210	207 (98.6)	0	3 (1.4)	0	0
HYPONATREMIA	210	200 (95.2)	10 (4.8)	0	0	0

090177e18e74aa79\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
ALANINE AMINOTRANSFERASE INCREASED	Adalimumab-Pfizer	69	*OTR	63	(91.3)	6	(8.7)	0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
	Total	63	(91.3)	6	(8.7)	0		0		0		69	(100.0)		
	Adalimumab-US	71	*OTR	51	(71.8)	15	(21.1)	0		1	(1.4)	0		67	(94.4)
			Grade 1	0		4	(5.6)	0		0		0		4	(5.6)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
	Total	51	(71.8)	19	(26.8)	0		1	(1.4)	0		71	(100.0)		
	Adalimumab-EU	70	*OTR	60	(85.7)	6	(8.6)	1	(1.4)	1	(1.4)	0		68	(97.1)
			Grade 1	1	(1.4)	1	(1.4)	0		0		0		2	(2.9)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
	Total	61	(87.1)	7	(10.0)	1	(1.4)	1	(1.4)	0		70	(100.0)		
	Total	210	*OTR	174	(82.9)	27	(12.9)	1	(0.5)	2	(1.0)	0		204	(97.1)
			Grade 1	1	(0.5)	5	(2.4)	0		0		0		6	(2.9)
Grade 2			0		0		0		0		0		0		
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total	175	(83.3)	32	(15.2)	1	(0.5)	2	(1.0)	0		210	(100.0)			

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
ALKALINE PHOSPHATASE INCREASED	Adalimumab-Pfizer	69	*OTR	69	(100.0)	0		0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(100.0)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	69	(97.2)	2	(2.8)	0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(97.2)	2	(2.8)	0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	69	(98.6)	1	(1.4)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(98.6)	1	(1.4)	0		0		0		70	(100.0)
	Total	210	*OTR	207	(98.6)	3	(1.4)	0		0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			207	(98.6)	3	(1.4)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
ASPARTATE AMINOTRANSFERASE INCREASED	Adalimumab-Pfizer	69	*OTR	64	(92.8)	4	(5.8)	0		0		0		68	(98.6)
			Grade 1	1	(1.4)	0		0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
	Total	65	(94.2)	4	(5.8)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	57	(80.3)	10	(14.1)	0		1	(1.4)	0		68	(95.8)
			Grade 1	1	(1.4)	2	(2.8)	0		0		0		3	(4.2)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
	Total	58	(81.7)	12	(16.9)	0		1	(1.4)	0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	57	(81.4)	9	(12.9)	1	(1.4)	1	(1.4)	0		68	(97.1)
			Grade 1	1	(1.4)	1	(1.4)	0		0		0		2	(2.9)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
	Total	58	(82.9)	10	(14.3)	1	(1.4)	1	(1.4)	0		0		70	(100.0)
	Total	210	*OTR	178	(84.8)	23	(11.0)	1	(0.5)	2	(1.0)	0		204	(97.1)
			Grade 1	3	(1.4)	3	(1.4)	0		0		0		6	(2.9)
Grade 2			0		0		0		0		0		0		
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total	181	(86.2)	26	(12.4)	1	(0.5)	2	(1.0)	0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
BLOOD BILIRUBIN INCREASED	Adalimumab-Pfizer	69	*OTR	57	(82.6)	5	(7.2)	2	(2.9)	0		0		64	(92.8)
			Grade 1	2	(2.9)	2	(2.9)	1	(1.4)	0		0		5	(7.2)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	59	(85.5)	7	(10.1)	3	(4.3)	0		0		69	(100.0)
	Adalimumab-US	71	*OTR	59	(83.1)	9	(12.7)	1	(1.4)	0		0		69	(97.2)
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 2	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	59	(83.1)	11	(15.5)	1	(1.4)	0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	63	(90.0)	4	(5.7)	0		0		0		67	(95.7)
			Grade 1	1	(1.4)	1	(1.4)	1	(1.4)	0		0		3	(4.3)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	64	(91.4)	5	(7.1)	1	(1.4)	0		0		70	(100.0)
	Total	210	*OTR	179	(85.2)	18	(8.6)	3	(1.4)	0		0		200	(95.2)
			Grade 1	3	(1.4)	4	(1.9)	2	(1.0)	0		0		9	(4.3)
			Grade 2	0		1	(0.5)	0		0		0		1	(0.5)
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			182	(86.7)	23	(11.0)	5	(2.4)	0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
CREATININE INCREASED	Adalimumab-Pfizer	69	*OTR	25	(36.2)	44	(63.8)	0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	25	(36.2)	44	(63.8)	0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	27	(38.0)	44	(62.0)	0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	27	(38.0)	44	(62.0)	0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	23	(32.9)	47	(67.1)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	23	(32.9)	47	(67.1)	0		0		0		70	(100.0)
	Total	210	*OTR	75	(35.7)	135	(64.3)	0		0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			75	(35.7)	135	(64.3)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade													
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total			
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		
HYPERCALCEMIA	Adalimumab-Pfizer	69	*OTR	62	(89.9)	6	(8.7)	0		0		0		68	(98.6)		
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)		
			Grade 2	0		0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0		0	
			Total	62	(89.9)	7	(10.1)	0		0		0		69	(100.0)		
	Adalimumab-US	71	*OTR	61	(85.9)	8	(11.3)	0		0		0		69	(97.2)		
			Grade 1	2	(2.8)	0		0		0		0		2	(2.8)		
			Grade 2	0		0		0		0		0		0			
			Grade 3	0		0		0		0		0		0			
			Grade 4	0		0		0		0		0		0			
			Total	63	(88.7)	8	(11.3)	0		0		0		71	(100.0)		
	Adalimumab-EU	70	*OTR	60	(85.7)	8	(11.4)	0		0		0		68	(97.1)		
			Grade 1	1	(1.4)	1	(1.4)	0		0		0		2	(2.9)		
			Grade 2	0		0		0		0		0		0			
			Grade 3	0		0		0		0		0		0			
			Grade 4	0		0		0		0		0		0			
			Total	61	(87.1)	9	(12.9)	0		0		0		70	(100.0)		
	Total	210	*OTR	183	(87.1)	22	(10.5)	0		0		0		205	(97.6)		
			Grade 1	3	(1.4)	2	(1.0)	0		0		0		5	(2.4)		
			Grade 2	0		0		0		0		0		0			
Grade 3			0		0		0		0		0		0				
Grade 4			0		0		0		0		0		0				
Total			186	(88.6)	24	(11.4)	0		0		0		210	(100.0)			

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade													
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total			
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		
HYPERGLYCEMIA	Adalimumab-Pfizer	69	*OTR	62	(89.9)	6	(8.7)	0		0		0		0	(98.6)		
			Grade 1	1	(1.4)	0		0		0		0		1	(1.4)		
			Grade 2	0		0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0		0	
			Total	63	(91.3)	6	(8.7)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	61	(85.9)	9	(12.7)	1	(1.4)	0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0		0	
			Total	61	(85.9)	9	(12.7)	1	(1.4)	0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	64	(91.4)	5	(7.1)	0		0		0		0		69	(98.6)
			Grade 1	1	(1.4)	0		0		0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0		0	
			Total	65	(92.9)	5	(7.1)	0		0		0		0		70	(100.0)
Total	210	*OTR	187	(89.0)	20	(9.5)	1	(0.5)	0		0		0		208	(99.0)	
		Grade 1	2	(1.0)	0		0		0		0		0		2	(1.0)	
		Grade 2	0		0		0		0		0		0		0		
		Grade 3	0		0		0		0		0		0		0		
		Grade 4	0		0		0		0		0		0		0		
		Total	189	(90.0)	20	(9.5)	1	(0.5)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPERKALEMIA	Adalimumab-Pfizer	69	*OTR	67	(97.1)	1	(1.4)	1	(1.4)	0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(97.1)	1	(1.4)	1	(1.4)	0		0		69	(100.0)
	Adalimumab-US	71	*OTR	65	(91.5)	4	(5.6)	2	(2.8)	0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	65	(91.5)	4	(5.6)	2	(2.8)	0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	63	(90.0)	6	(8.6)	1	(1.4)	0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	63	(90.0)	6	(8.6)	1	(1.4)	0		0		70	(100.0)
Total	210	*OTR	195	(92.9)	11	(5.2)	4	(1.9)	0		0		210	(100.0)	
		Grade 1	0		0		0		0		0		0		
		Grade 2	0		0		0		0		0		0		
		Grade 3	0		0		0		0		0		0		
		Grade 4	0		0		0		0		0		0		
		Total	195	(92.9)	11	(5.2)	4	(1.9)	0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPERNATREMIA	Adalimumab-Pfizer	69	*OTR	67	(97.1)	2	(2.9)	0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(97.1)	2	(2.9)	0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	68	(95.8)	2	(2.8)	0		0		0		70	(98.6)
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(95.8)	3	(4.2)	0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	67	(95.7)	2	(2.9)	0		0		0		69	(98.6)
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(95.7)	3	(4.3)	0		0		0		70	(100.0)
	Total	210	*OTR	202	(96.2)	6	(2.9)	0		0		0		208	(99.0)
			Grade 1	0		2	(1.0)	0		0		0		2	(1.0)
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			202	(96.2)	8	(3.8)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPOALBUMINEMIA	Adalimumab-Pfizer	69	*OTR	69	(100.0)	0		0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(100.0)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	71	(100.0)	0		0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	71	(100.0)	0		0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	70	(100.0)	0		0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	70	(100.0)	0		0		0		0		70	(100.0)
	Total	210	*OTR	210	(100.0)	0		0		0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			210	(100.0)	0		0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPOCALCEMIA	Adalimumab-Pfizer	69	*OTR	69	(100.0)	0		0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(100.0)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	71	(100.0)	0		0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	71	(100.0)	0		0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	70	(100.0)	0		0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	70	(100.0)	0		0		0		0		70	(100.0)
	Total	210	*OTR	210	(100.0)	0		0		0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			210	(100.0)	0		0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

				Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Parameter	Treatment Group	N	Baseline Grade	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPOGLYCEMIA	Adalimumab-Pfizer	69	*OTR	69	(100.0)	0		0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(100.0)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	71	(100.0)	0		0		0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	71	(100.0)	0		0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	69	(98.6)	1	(1.4)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(98.6)	1	(1.4)	0		0		0		70	(100.0)
	Total	210	*OTR	209	(99.5)	1	(0.5)	0		0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			209	(99.5)	1	(0.5)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPOKALEMIA	Adalimumab-Pfizer	69	*OTR	69	(100.0)	0		0		0		0		69	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	69	(100.0)	0		0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	70	(98.6)	0		1	(1.4)	0		0		71	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	70	(98.6)	0		1	(1.4)	0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	68	(97.1)	0		2	(2.9)	0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(97.1)	0		2	(2.9)	0		0		70	(100.0)
	Total	210	*OTR	207	(98.6)	0		3	(1.4)	0		0		210	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			207	(98.6)	0		3	(1.4)	0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.1.6.2
PF-06410293 Protocol B5381001
Shift Summary Results of Labs by Maximum CTCAE Grade (Chemistries) - Safety Analysis Set

Parameter	Treatment Group	N	Baseline Grade	Maximum CTCAE Grade											
				*OTR		Grade 1		Grade 2		Grade 3		Grade 4		Total	
				n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
HYPONATREMIA	Adalimumab-Pfizer	69	*OTR	67	(97.1)	1	(1.4)	0		0		0		68	(98.6)
			Grade 1	1	(1.4)	0		0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	68	(98.6)	1	(1.4)	0		0		0		69	(100.0)
	Adalimumab-US	71	*OTR	65	(91.5)	5	(7.0)	0		0		0		70	(98.6)
			Grade 1	0		1	(1.4)	0		0		0		1	(1.4)
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	65	(91.5)	6	(8.5)	0		0		0		71	(100.0)
	Adalimumab-EU	70	*OTR	67	(95.7)	3	(4.3)	0		0		0		70	(100.0)
			Grade 1	0		0		0		0		0		0	
			Grade 2	0		0		0		0		0		0	
			Grade 3	0		0		0		0		0		0	
			Grade 4	0		0		0		0		0		0	
			Total	67	(95.7)	3	(4.3)	0		0		0		70	(100.0)
	Total	210	*OTR	199	(94.8)	9	(4.3)	0		0		0		208	(99.0)
			Grade 1	1	(0.5)	1	(0.5)	0		0		0		2	(1.0)
			Grade 2	0		0		0		0		0		0	
Grade 3			0		0		0		0		0		0		
Grade 4			0		0		0		0		0		0		
Total			200	(95.2)	10	(4.8)	0		0		0		210	(100.0)	

*OTR-Outside the Toxicity Range: non-missing lab value that is not toxic (falls outside grading range) for corresponding lab parameter.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.1.1.3 Date of SDTM Dataset Creation: 11MAY2018 Date of Table Generation: 15MAY2018 (23:14)

090177e18e74aa7a\Final\Final On: 30-May-2018 05:32 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	122.1	120.4	120.5	121.0
		Std. Dev.	9.58	7.88	8.49	8.66
		Median	121.0	121.0	121.0	121.0
		Min	95.0	104.0	99.0	95.0
		Max	145.0	140.0	140.0	145.0
Day 0	0H	n	69	71	69	209
		Mean	121.3	122.3	121.9	121.8
		Std. Dev.	9.81	9.41	9.44	9.52
		Median	122.0	121.0	121.0	121.0
		Min	98.0	104.0	102.0	98.0
		Max	147.0	154.0	149.0	154.0
Day 1	0H	n	69	71	70	210
		Mean	114.7	114.7	114.6	114.7
		Std. Dev.	9.03	8.92	8.92	8.91
		Median	115.0	115.0	115.0	115.0
		Min	93.0	94.0	95.0	93.0
		Max	134.0	140.0	136.0	140.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
	3H	n	69	71	70	210
		Mean	113.6	113.3	113.2	113.4
		Std. Dev.	9.78	9.48	8.06	9.09
		Median	114.0	113.0	113.5	114.0
		Min	93.0	94.0	95.0	93.0
		Max	134.0	138.0	134.0	138.0
Day 2	24H	n	69	71	70	210
		Mean	114.4	114.1	113.4	114.0
		Std. Dev.	8.71	7.37	8.91	8.32
		Median	115.0	113.0	112.5	114.0
		Min	89.0	98.0	98.0	89.0
		Max	131.0	131.0	142.0	142.0
Day 3	48H	n	69	71	70	210
		Mean	115.7	115.2	114.3	115.1
		Std. Dev.	8.45	9.32	8.51	8.75
		Median	116.0	114.0	114.0	115.0
		Min	93.0	92.0	96.0	92.0
		Max	135.0	134.0	141.0	141.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 4	72H	n	68	71	70	209
		Mean	114.6	114.0	114.9	114.5
		Std. Dev.	7.86	8.08	9.41	8.45
		Median	115.0	114.0	113.5	114.0
		Min	96.0	93.0	99.0	93.0
		Max	130.0	131.0	139.0	139.0
Day 5	96H	n	69	71	70	210
		Mean	116.8	116.2	115.9	116.3
		Std. Dev.	9.55	7.98	8.22	8.57
		Median	118.0	115.0	116.0	116.0
		Min	92.0	92.0	96.0	92.0
		Max	136.0	132.0	138.0	138.0
Day 6	120H	n	69	71	70	210
		Mean	116.4	115.9	115.2	115.8
		Std. Dev.	9.29	9.17	9.63	9.34
		Median	115.0	116.0	115.0	116.0
		Min	96.0	90.0	97.0	90.0
		Max	135.0	136.0	143.0	143.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 7	144H	n	68	71	70	209
		Mean	116.3	117.0	116.4	116.6
		Std. Dev.	7.80	9.39	7.93	8.38
		Median	115.5	116.0	115.0	116.0
		Min	98.0	92.0	105.0	92.0
		Max	134.0	154.0	138.0	154.0
Day 8	168H	n	69	71	70	210
		Mean	117.7	116.1	118.1	117.3
		Std. Dev.	9.57	9.74	9.50	9.59
		Median	117.0	116.0	118.0	117.0
		Min	90.0	92.0	101.0	90.0
		Max	141.0	143.0	143.0	143.0
Day 9	192H	n	68	71	70	209
		Mean	120.9	121.5	120.8	121.1
		Std. Dev.	9.96	9.70	9.16	9.57
		Median	122.0	121.0	121.0	121.0
		Min	88.0	98.0	101.0	88.0
		Max	142.0	144.0	143.0	144.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 12	264H	n	68	69	70	207
		Mean	121.5	120.8	118.9	120.4
		Std. Dev.	8.99	7.86	8.92	8.63
		Median	121.0	121.0	118.0	120.0
		Min	103.0	100.0	97.0	97.0
		Max	140.0	138.0	141.0	141.0
Day 15	336H	n	68	71	69	208
		Mean	120.2	120.5	118.9	119.9
		Std. Dev.	11.04	9.01	9.05	9.71
		Median	120.0	119.0	118.0	119.0
		Min	98.0	99.0	97.0	97.0
		Max	144.0	141.0	145.0	145.0
Day 22	504H	n	67	71	69	207
		Mean	121.2	120.8	119.3	120.4
		Std. Dev.	9.35	9.15	9.31	9.26
		Median	121.0	121.0	120.0	121.0
		Min	98.0	97.0	98.0	97.0
		Max	142.0	142.0	138.0	142.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 29	672H	n	67	70	70	207
		Mean	121.4	119.3	119.4	120.0
		Std. Dev.	9.62	8.90	8.96	9.17
		Median	123.0	120.0	118.5	120.0
		Min	94.0	99.0	99.0	94.0
		Max	147.0	148.0	146.0	148.0
Day 36	840H	n	67	69	70	206
		Mean	121.2	120.7	120.0	120.6
		Std. Dev.	9.08	9.78	8.55	9.12
		Median	121.0	121.0	119.5	120.0
		Min	101.0	89.0	101.0	89.0
		Max	143.0	143.0	141.0	143.0
Day 43	1008H	n	67	71	70	208
		Mean	120.7	121.0	119.8	120.5
		Std. Dev.	8.97	9.43	9.22	9.18
		Median	121.0	122.0	121.0	121.0
		Min	96.0	100.0	97.0	96.0
		Max	138.0	143.0	138.0	143.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE SYSTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	120.7	122.8	119.4	121.0
		Std. Dev.	9.71	8.30	9.89	9.38
		Median	120.0	123.0	120.0	121.0
		Min	99.0	103.0	93.0	93.0
		Max	141.0	140.0	141.0	141.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	73.0	72.7	72.1	72.6
		Std. Dev.	7.77	5.79	6.78	6.80
		Median	72.0	73.0	71.5	72.0
		Min	57.0	62.0	59.0	57.0
		Max	88.0	87.0	95.0	95.0
Day 0	0H	n	69	71	69	209
		Mean	70.3	70.8	70.9	70.7
		Std. Dev.	6.83	6.65	6.71	6.70
		Median	69.0	70.0	69.0	69.0
		Min	53.0	50.0	60.0	50.0
		Max	92.0	89.0	97.0	97.0
Day 1	0H	n	69	71	70	210
		Mean	67.7	67.8	67.8	67.8
		Std. Dev.	6.20	5.39	6.16	5.89
		Median	67.0	68.0	67.0	67.0
		Min	51.0	52.0	58.0	51.0
		Max	86.0	83.0	98.0	98.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
	3H	n	69	71	70	210
		Mean	67.0	67.4	67.1	67.2
		Std. Dev.	5.90	6.77	6.12	6.25
		Median	67.0	67.0	66.0	67.0
		Min	49.0	51.0	57.0	49.0
		Max	79.0	92.0	98.0	98.0
Day 2	24H	n	69	71	70	210
		Mean	67.9	67.0	67.2	67.3
		Std. Dev.	5.05	5.27	5.97	5.43
		Median	67.0	66.0	67.0	67.0
		Min	59.0	54.0	57.0	54.0
		Max	79.0	80.0	99.0	99.0
Day 3	48H	n	69	71	70	210
		Mean	68.3	67.7	67.6	67.9
		Std. Dev.	5.05	5.98	6.40	5.82
		Median	67.0	67.0	67.0	67.0
		Min	57.0	52.0	56.0	52.0
		Max	81.0	87.0	97.0	97.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 4	72H	n	68	71	70	209
		Mean	68.4	67.9	68.0	68.1
		Std. Dev.	5.39	5.54	6.67	5.87
		Median	68.0	67.0	67.0	67.0
		Min	57.0	51.0	58.0	51.0
		Max	87.0	80.0	97.0	97.0
Day 5	96H	n	69	71	70	210
		Mean	69.0	68.6	68.7	68.8
		Std. Dev.	6.13	5.70	6.25	6.00
		Median	68.0	68.0	68.0	68.0
		Min	55.0	56.0	57.0	55.0
		Max	83.0	86.0	94.0	94.0
Day 6	120H	n	69	71	70	210
		Mean	68.3	68.3	68.2	68.3
		Std. Dev.	5.68	6.61	7.16	6.49
		Median	68.0	67.0	67.0	67.0
		Min	55.0	49.0	53.0	49.0
		Max	84.0	90.0	98.0	98.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 7	144H	n	68	71	70	209
		Mean	68.6	69.3	68.5	68.8
		Std. Dev.	5.53	6.83	7.02	6.48
		Median	67.0	68.0	67.0	68.0
		Min	57.0	53.0	53.0	53.0
		Max	84.0	95.0	101.0	101.0
Day 8	168H	n	69	71	70	210
		Mean	68.4	68.4	68.9	68.6
		Std. Dev.	6.75	5.67	6.78	6.39
		Median	67.0	67.0	67.0	67.0
		Min	51.0	53.0	58.0	51.0
		Max	85.0	83.0	99.0	99.0
Day 9	192H	n	68	71	70	209
		Mean	70.8	71.8	71.3	71.3
		Std. Dev.	5.76	6.57	6.03	6.12
		Median	71.0	71.0	70.5	71.0
		Min	55.0	57.0	59.0	55.0
		Max	83.0	86.0	90.0	90.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 12	264H	n	68	69	70	207
		Mean	71.2	71.7	70.7	71.2
		Std. Dev.	6.14	6.23	6.27	6.20
		Median	71.0	70.0	69.0	70.0
		Min	55.0	60.0	63.0	55.0
		Max	84.0	90.0	89.0	90.0
Day 15	336H	n	68	71	69	208
		Mean	71.4	72.1	71.4	71.7
		Std. Dev.	6.24	6.29	7.36	6.63
		Median	70.0	71.0	69.0	70.0
		Min	60.0	59.0	60.0	59.0
		Max	91.0	94.0	96.0	96.0
Day 22	504H	n	67	71	69	207
		Mean	71.7	72.0	70.8	71.5
		Std. Dev.	7.14	6.20	6.91	6.74
		Median	70.0	71.0	69.0	70.0
		Min	57.0	58.0	56.0	56.0
		Max	90.0	89.0	88.0	90.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 29	672H	n	67	70	70	207
		Mean	72.3	71.3	71.0	71.5
		Std. Dev.	6.91	6.10	6.24	6.41
		Median	72.0	70.0	69.0	71.0
		Min	55.0	58.0	61.0	55.0
		Max	91.0	86.0	95.0	95.0
Day 36	840H	n	67	69	70	206
		Mean	71.0	71.6	70.8	71.1
		Std. Dev.	6.45	6.65	6.06	6.37
		Median	70.0	71.0	70.0	70.5
		Min	56.0	59.0	59.0	56.0
		Max	91.0	89.0	87.0	91.0
Day 43	1008H	n	67	71	70	208
		Mean	72.0	71.2	71.1	71.4
		Std. Dev.	6.17	6.08	6.38	6.20
		Median	71.0	70.0	69.0	70.0
		Min	59.0	59.0	59.0	59.0
		Max	86.0	90.0	88.0	90.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE DIASTOLIC BLOOD PRESSURE (MMHG)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	71.7	72.9	71.5	72.0
		Std. Dev.	6.61	6.50	7.11	6.74
		Median	71.0	72.0	69.0	71.0
		Min	59.0	59.0	60.0	59.0
		Max	88.0	88.0	97.0	97.0

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	58.4	58.5	57.9	58.3
		Std. Dev.	9.02	8.77	9.66	9.12
		Median	58.0	58.0	57.0	58.0
		Min	37.0	40.0	40.0	37.0
		Max	90.0	80.0	85.0	90.0
Day 0	0H	n	69	71	69	209
		Mean	64.7	65.6	63.9	64.7
		Std. Dev.	10.38	11.36	8.81	10.22
		Median	64.0	66.0	63.0	64.0
		Min	44.0	41.0	45.0	41.0
		Max	94.0	96.0	86.0	96.0
Day 1	0H	n	69	71	70	210
		Mean	57.9	58.5	58.3	58.2
		Std. Dev.	8.98	8.69	7.13	8.27
		Median	57.0	58.0	58.0	58.0
		Min	41.0	34.0	41.0	34.0
		Max	85.0	80.0	79.0	85.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
	3H	n	69	71	70	210
		Mean	58.4	58.0	57.9	58.1
		Std. Dev.	8.59	7.65	7.67	7.94
		Median	58.0	58.0	58.5	58.0
		Min	40.0	38.0	42.0	38.0
		Max	80.0	76.0	82.0	82.0
Day 2	24H	n	69	71	70	210
		Mean	57.8	58.8	58.7	58.4
		Std. Dev.	8.29	9.39	8.31	8.66
		Median	57.0	57.0	58.0	57.0
		Min	40.0	40.0	43.0	40.0
		Max	76.0	87.0	89.0	89.0
Day 3	48H	n	69	71	70	210
		Mean	57.8	59.6	59.1	58.8
		Std. Dev.	7.89	9.29	7.31	8.20
		Median	58.0	58.0	58.5	58.0
		Min	42.0	39.0	43.0	39.0
		Max	80.0	83.0	78.0	83.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 4	72H	n	68	71	70	209
		Mean	58.3	61.0	58.9	59.4
		Std. Dev.	8.19	9.40	7.84	8.55
		Median	57.5	60.0	58.0	59.0
		Min	41.0	44.0	44.0	41.0
		Max	79.0	90.0	88.0	90.0
Day 5	96H	n	69	71	70	210
		Mean	59.1	60.5	59.0	59.5
		Std. Dev.	8.37	10.01	7.32	8.64
		Median	60.0	60.0	58.0	59.0
		Min	41.0	39.0	45.0	39.0
		Max	77.0	91.0	90.0	91.0
Day 6	120H	n	69	71	70	210
		Mean	60.1	60.3	60.6	60.3
		Std. Dev.	7.65	9.63	8.95	8.75
		Median	60.0	59.0	60.0	60.0
		Min	43.0	38.0	43.0	38.0
		Max	76.0	85.0	90.0	90.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 7	144H	n	68	71	70	209
		Mean	60.6	61.9	60.8	61.1
		Std. Dev.	8.45	11.52	8.55	9.60
		Median	59.5	60.0	59.5	60.0
		Min	40.0	42.0	45.0	40.0
		Max	80.0	114.0	94.0	114.0
Day 8	168H	n	69	71	70	210
		Mean	61.0	62.8	61.6	61.8
		Std. Dev.	8.24	12.14	8.65	9.84
		Median	61.0	61.0	62.0	61.0
		Min	41.0	39.0	44.0	39.0
		Max	85.0	126.0	86.0	126.0
Day 9	192H	n	68	71	70	209
		Mean	65.2	67.2	66.4	66.3
		Std. Dev.	10.11	11.53	9.68	10.46
		Median	65.0	64.0	64.0	64.0
		Min	42.0	49.0	47.0	42.0
		Max	97.0	111.0	95.0	111.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 12	264H	n	68	69	70	207
		Mean	66.0	64.9	65.4	65.4
		Std. Dev.	11.18	10.70	10.04	10.60
		Median	64.0	65.0	63.5	64.0
		Min	44.0	41.0	42.0	41.0
		Max	97.0	90.0	90.0	97.0
Day 15	336H	n	68	71	69	208
		Mean	62.5	62.5	64.0	63.0
		Std. Dev.	9.79	10.44	9.72	9.97
		Median	62.0	62.0	64.0	62.0
		Min	43.0	42.0	37.0	37.0
		Max	90.0	97.0	93.0	97.0
Day 22	504H	n	67	71	69	207
		Mean	64.9	64.7	63.9	64.5
		Std. Dev.	9.13	9.96	8.96	9.33
		Median	64.0	63.0	65.0	64.0
		Min	49.0	45.0	38.0	38.0
		Max	87.0	87.0	95.0	95.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 29	672H	n	67	70	70	207
		Mean	62.7	63.2	63.8	63.2
		Std. Dev.	9.94	9.24	9.81	9.63
		Median	62.0	64.5	62.5	63.0
		Min	43.0	45.0	41.0	41.0
		Max	87.0	85.0	91.0	91.0
Day 36	840H	n	67	69	70	206
		Mean	64.9	65.6	64.8	65.1
		Std. Dev.	11.46	10.01	10.04	10.47
		Median	63.0	66.0	65.5	65.0
		Min	48.0	45.0	42.0	42.0
		Max	111.0	91.0	94.0	111.0
Day 43	1008H	n	67	71	70	208
		Mean	63.3	64.2	64.6	64.0
		Std. Dev.	9.78	10.76	10.73	10.41
		Median	63.0	64.0	65.0	64.0
		Min	47.0	42.0	39.0	39.0
		Max	87.0	91.0	97.0	97.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SUPINE PULSE RATE (BPM)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	62.7	64.7	63.2	63.5
		Std. Dev.	9.70	11.18	10.68	10.53
		Median	62.0	65.0	62.0	62.0
		Min	43.0	39.0	40.0	39.0
		Max	87.0	100.0	94.0	100.0

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
SPO2 PULSE OXIMETRY % (%)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 1	0H	n	69	71	70	210
		Mean	98.3	98.1	98.1	98.2
		Std. Dev.	1.38	1.34	1.35	1.35
		Median	98.0	98.0	98.0	98.0
		Min	95.0	96.0	95.0	95.0
		Max	100.0	100.0	100.0	100.0
	3H	n	68	71	68	207
		Mean	98.4	98.2	98.2	98.2
		Std. Dev.	1.37	1.33	1.31	1.33
		Median	99.0	98.0	98.0	98.0
		Min	95.0	95.0	94.0	94.0
		Max	100.0	100.0	100.0	100.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
SCREENING		n	69	71	70	210
		Mean	36.2	36.2	36.2	36.2
		Std. Dev.	0.29	0.37	0.38	0.35
		Median	36.2	36.3	36.2	36.2
		Min	35.6	35.2	35.2	35.2
		Max	36.9	37.2	37.2	37.2
Day 0	0H	n	69	71	70	210
		Mean	36.5	36.4	36.4	36.4
		Std. Dev.	0.37	0.41	0.39	0.39
		Median	36.5	36.4	36.4	36.4
		Min	35.4	35.2	35.4	35.2
		Max	37.4	37.2	37.3	37.4
Day 1	0H	n	69	71	70	210
		Mean	36.2	36.1	36.1	36.1
		Std. Dev.	0.33	0.32	0.34	0.33
		Median	36.2	36.2	36.2	36.2
		Min	35.3	35.2	35.4	35.2
		Max	37.0	36.7	36.8	37.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
	3H	n	69	71	70	210
		Mean	36.3	36.2	36.3	36.3
		Std. Dev.	0.33	0.36	0.34	0.35
		Median	36.4	36.3	36.3	36.3
		Min	35.4	35.1	35.3	35.1
		Max	37.2	37.0	36.9	37.2
Day 2	24H	n	69	71	70	210
		Mean	36.2	36.2	36.3	36.2
		Std. Dev.	0.32	0.29	0.32	0.31
		Median	36.2	36.2	36.3	36.2
		Min	35.3	35.4	35.4	35.3
		Max	36.7	36.8	36.9	36.9
Day 3	48H	n	69	71	70	210
		Mean	36.2	36.2	36.2	36.2
		Std. Dev.	0.35	0.37	0.30	0.34
		Median	36.2	36.2	36.3	36.2
		Min	35.1	35.1	35.4	35.1
		Max	36.8	37.0	36.8	37.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 4	72H	n	69	71	70	210
		Mean	36.2	36.2	36.2	36.2
		Std. Dev.	0.38	0.37	0.36	0.37
		Median	36.2	36.2	36.2	36.2
		Min	35.2	35.1	35.3	35.1
		Max	36.9	37.0	37.0	37.0
Day 5	96H	n	69	71	70	210
		Mean	36.2	36.1	36.3	36.2
		Std. Dev.	0.30	0.31	0.36	0.33
		Median	36.2	36.2	36.3	36.2
		Min	35.4	35.4	35.4	35.4
		Max	36.9	36.9	37.2	37.2
Day 6	120H	n	69	71	70	210
		Mean	36.2	36.1	36.2	36.2
		Std. Dev.	0.31	0.36	0.30	0.32
		Median	36.2	36.2	36.3	36.2
		Min	35.3	35.3	35.5	35.3
		Max	36.8	36.9	36.8	36.9

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 7	144H	n	67	71	70	208
		Mean	36.3	36.2	36.2	36.2
		Std. Dev.	0.31	0.39	0.35	0.36
		Median	36.3	36.2	36.3	36.3
		Min	35.3	35.3	35.3	35.3
		Max	37.2	36.8	37.0	37.2
Day 8	168H	n	69	71	70	210
		Mean	36.3	36.3	36.3	36.3
		Std. Dev.	0.31	0.38	0.32	0.34
		Median	36.4	36.3	36.4	36.4
		Min	35.5	35.3	35.5	35.3
		Max	36.9	37.4	37.0	37.4
Day 9	192H	n	68	71	70	209
		Mean	36.3	36.3	36.3	36.3
		Std. Dev.	0.33	0.36	0.38	0.35
		Median	36.3	36.3	36.3	36.3
		Min	35.6	35.3	35.3	35.3
		Max	36.9	37.1	37.2	37.2

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 12	264H	n	68	69	70	207
		Mean	36.2	36.2	36.2	36.2
		Std. Dev.	0.43	0.45	0.36	0.41
		Median	36.2	36.2	36.2	36.2
		Min	35.2	35.2	35.3	35.2
		Max	37.3	37.3	36.9	37.3
Day 15	336H	n	68	71	69	208
		Mean	36.2	36.1	36.2	36.1
		Std. Dev.	0.42	0.42	0.39	0.41
		Median	36.2	36.2	36.2	36.2
		Min	35.3	35.0	35.3	35.0
		Max	37.2	36.9	37.5	37.5
Day 22	504H	n	67	71	69	207
		Mean	36.2	36.2	36.2	36.2
		Std. Dev.	0.43	0.42	0.37	0.41
		Median	36.3	36.2	36.2	36.2
		Min	35.3	35.2	35.3	35.2
		Max	37.2	37.0	36.9	37.2

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 29	672H	n	67	70	70	207
		Mean	36.2	36.1	36.1	36.1
		Std. Dev.	0.38	0.36	0.41	0.38
		Median	36.2	36.1	36.2	36.2
		Min	35.3	35.4	35.3	35.3
		Max	36.9	37.0	37.3	37.3
Day 36	840H	n	67	69	70	206
		Mean	36.2	36.1	36.2	36.2
		Std. Dev.	0.41	0.32	0.41	0.38
		Median	36.2	36.2	36.3	36.2
		Min	35.1	35.4	35.1	35.1
		Max	37.0	37.0	37.2	37.2
Day 43	1008H	n	67	71	70	208
		Mean	36.2	36.1	36.2	36.1
		Std. Dev.	0.40	0.36	0.35	0.37
		Median	36.2	36.1	36.2	36.2
		Min	35.2	35.2	35.2	35.2
		Max	37.0	37.2	36.8	37.2

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
TEMPERATURE (C)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 71	1680H	n	69	71	69	209
		Mean	36.3	36.2	36.3	36.2
		Std. Dev.	0.33	0.40	0.43	0.39
		Median	36.3	36.3	36.3	36.3
		Min	35.4	35.2	35.2	35.2
		Max	37.0	37.0	37.3	37.3

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Unplanned readings have been excluded from the presentation.
PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
SCREENING		n	69	70	70	209
		Mean	15.0	15.4	15.7	15.4
		Std. Dev.	2.51	2.91	2.54	2.67
		Median	14.0	16.0	16.0	16.0
		Min	10.0	8.0	10.0	8.0
		Max	22.0	24.0	20.0	24.0
Day 0	0H	n	69	71	70	210
		Mean	15.7	16.5	15.6	15.9
		Std. Dev.	2.53	2.69	2.86	2.71
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	8.0	8.0
		Max	22.0	22.0	22.0	22.0
Day 1	0H	n	69	71	69	209
		Mean	14.6	14.6	14.9	14.7
		Std. Dev.	2.56	2.59	2.78	2.63
		Median	14.0	14.0	16.0	15.0
		Min	10.0	8.0	8.0	8.0
		Max	20.0	20.0	20.0	20.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
	3H	n	69	71	70	210
		Mean	14.6	14.2	15.2	14.7
		Std. Dev.	2.36	2.72	2.32	2.50
		Median	14.0	14.0	16.0	16.0
		Min	10.0	8.0	10.0	8.0
		Max	20.0	20.0	20.0	20.0
Day 2	24H	n	69	71	70	210
		Mean	14.9	15.1	15.2	15.1
		Std. Dev.	2.51	2.55	2.71	2.58
		Median	16.0	14.0	15.0	15.0
		Min	10.0	10.0	8.0	8.0
		Max	20.0	20.0	24.0	24.0
Day 3	48H	n	69	71	70	210
		Mean	14.7	15.0	15.0	14.9
		Std. Dev.	2.04	2.29	2.74	2.37
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	8.0	8.0
		Max	20.0	20.0	24.0	24.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 4	72H	n	69	71	70	210
		Mean	14.9	14.9	14.6	14.8
		Std. Dev.	2.40	2.55	2.71	2.55
		Median	16.0	14.0	14.0	15.5
		Min	10.0	8.0	10.0	8.0
		Max	24.0	20.0	22.0	24.0
Day 5	96H	n	69	71	70	210
		Mean	14.7	14.9	15.2	14.9
		Std. Dev.	2.76	2.70	3.13	2.86
		Median	14.0	16.0	16.0	16.0
		Min	10.0	8.0	4.0	4.0
		Max	20.0	20.0	26.0	26.0
Day 6	120H	n	69	70	70	209
		Mean	14.8	15.4	15.1	15.1
		Std. Dev.	2.50	2.68	2.63	2.61
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	10.0	10.0
		Max	20.0	24.0	24.0	24.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 7	144H	n	66	71	70	207
		Mean	14.7	14.6	15.0	14.8
		Std. Dev.	2.29	2.86	2.65	2.61
		Median	15.0	14.0	14.0	14.0
		Min	8.0	6.0	10.0	6.0
		Max	20.0	22.0	22.0	22.0
Day 8	168H	n	68	70	69	207
		Mean	15.0	14.8	14.7	14.8
		Std. Dev.	2.57	2.95	2.49	2.67
		Median	15.0	16.0	14.0	16.0
		Min	8.0	8.0	10.0	8.0
		Max	20.0	22.0	22.0	22.0
Day 9	192H	n	68	71	70	209
		Mean	15.5	15.8	15.3	15.5
		Std. Dev.	2.58	3.23	2.93	2.92
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	8.0	8.0
		Max	20.0	26.0	20.0	26.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 12	264H	n	68	69	70	207
		Mean	15.7	16.0	15.5	15.7
		Std. Dev.	2.60	3.16	2.84	2.87
		Median	16.0	16.0	16.0	16.0
		Min	10.0	6.0	8.0	6.0
		Max	22.0	22.0	20.0	22.0
Day 15	336H	n	68	71	69	208
		Mean	16.1	15.3	15.3	15.5
		Std. Dev.	2.96	2.72	2.59	2.77
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	8.0	8.0
		Max	26.0	22.0	22.0	26.0
Day 22	504H	n	67	71	69	207
		Mean	16.2	16.2	15.9	16.1
		Std. Dev.	2.74	2.55	2.68	2.64
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	10.0	10.0
		Max	20.0	24.0	22.0	24.0

Unplanned readings have been excluded from the presentation.
 PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 29	672H	n	66	70	69	205
		Mean	15.8	15.7	15.5	15.6
		Std. Dev.	2.66	2.86	3.13	2.88
		Median	16.0	16.0	16.0	16.0
		Min	12.0	8.0	10.0	8.0
		Max	20.0	20.0	26.0	26.0
Day 36	840H	n	67	69	70	206
		Mean	15.4	15.7	15.6	15.6
		Std. Dev.	2.72	2.85	2.57	2.71
		Median	16.0	16.0	16.0	16.0
		Min	10.0	8.0	10.0	8.0
		Max	22.0	22.0	20.0	22.0
Day 43	1008H	n	67	71	70	208
		Mean	15.3	15.0	15.3	15.2
		Std. Dev.	2.45	2.55	3.13	2.72
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	8.0	8.0
		Max	20.0	20.0	24.0	24.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)

090177e18ebdb7bf\Final\Final On: 15-Jun-2018 05:27 (GMT)

Table 14.3.4.2.1.1
PF-06410293 Protocol B5381001
Vital Signs Data Absolute Values - Safety Analysis Set
RESPIRATORY RATE (BREATHS/MIN)

			Adalimumab-Pfizer (N=69)	Adalimumab-US (N=71)	Adalimumab-EU (N=70)	Total (N=210)
Visit	Planned Time Post Dose (HOURS)	Summary Statistics				
Day 71	1680H	n	68	71	69	208
		Mean	15.5	15.2	15.4	15.4
		Std. Dev.	2.82	2.65	3.07	2.83
		Median	16.0	16.0	16.0	16.0
		Min	10.0	10.0	6.0	6.0
		Max	22.0	20.0	24.0	24.0

Unplanned readings have been excluded from the presentation.

PFIZER CONFIDENTIAL Source Data: Table 16.2.8.2.1 Date of SDTM Dataset Creation: 27APR2018 Date of Table Generation: 14JUN2018 (01:15)